scispace - formally typeset
K

Kim A. Floyd-Hawkins

Researcher at University of California, Davis

Publications -  5
Citations -  1100

Kim A. Floyd-Hawkins is an academic researcher from University of California, Davis. The author has contributed to research in topics: Bartonella henselae & Bartonella clarridgeiae. The author has an hindex of 5, co-authored 5 publications receiving 1036 citations.

Papers
More filters
Journal ArticleDOI

Experimental transmission of Bartonella henselae by the cat flea.

TL;DR: Data demonstrate that the cat flea readily transmits B. henselae to cats, and control of feline infestation with this arthropod vector may provide an important strategy for the prevention of infection of both humans and cats.
Journal ArticleDOI

Bartonella henselae prevalence in domestic cats in California: risk factors and association between bacteremia and antibody titers.

TL;DR: Seronegative cats may be more appropriate pets for immunocompromised individuals who are at increased risk for developing severe B. henselae disease.
Journal ArticleDOI

Experimental and natural infection with Bartonella henselae in domestic cats

TL;DR: These studies indicate that B. henselae exists in an almost perfect host-parasite relationship with its feline host, but that most cats can ultimately rid themselves of the infection.
Journal ArticleDOI

Homologous protection but lack of heterologous protection by various species and types of Bartonella in specific pathogen-free cats.

TL;DR: In a series of experiments, 21 SPF cats were experimentally infected by the intradermal route with 10(5)-10(10) colony-forming units/ml of either B. henselae type II, or a new strain 'Humboldt' isolated from a mountain lion (4 cats), to determine if cats become resistant to re-infection by the same strain or various types or species of Bartonella.
Journal ArticleDOI

Cyclosporine pharmacokinetics in cats following topical ocular administration.

TL;DR: Topical ocular administration of cyclosporine in cats offers a possible alternative method of treatment for individuals intolerant of oral administration and might also replace the need for intravenous administration of CYP during perioperative periods or during periods of vomiting and nausea associated with rejection or other illnesses.